<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335711">
  <stage>Registered</stage>
  <submitdate>13/07/2010</submitdate>
  <approvaldate>19/07/2010</approvaldate>
  <actrnumber>ACTRN12610000577011</actrnumber>
  <trial_identification>
    <studytitle>Peppermint versus dimethicone in the treatment of infantile colic: a randomized clinical trial</studytitle>
    <scientifictitle>A randomized controlled crossover study comparing the clinical response of Peppermint against Dimethicone in infants with colic</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infantile colic</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The intervention will be the administration of Peppermint  for the treatment of infantile colic. The drug will be administered orally during the episode of colic, up to four times daily. The dosage will be 20 mg/Kg administered in the form of drops. Peppermint and dimethicone will be administered for one week each in a randomised order with wash-out period of 24 hours. The duration of the follow-up of the  intervention/control will be two weeks.</interventions>
    <comparator>The control group will be given Dimethicone, a drug commonly used to control infantile colic. The drug also will be administered orally during the episode of colic, up to four times daily for a period of one week. The dosage will be 20 mg/Kg administered in the form of drops. The duration of the follow-up of the intervention/control will be two weeks.   
The washout period before participants are crossed over to receive the other treatment studied in this trial will be 24 hours.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Crying time. It will be assessed by a stopwatch previously provides to parents.</outcome>
      <timepoint>Minutes per day at baseline and 1 week after intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of daily episodes of colic noted by parents.</outcome>
      <timepoint>At baseline and 1 week after intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>It will be studied infants with colic (crying for more than 3 hours on at least three ocasions a week), but otherwise healthy.</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Days</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Days</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Low birth weight and prematurity;
Gastrointestinal, neurological or allergic diseases</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation involved contacting the holder of the allocation schedule who was "off-site" or at central administration</concealment>
    <sequence>Simple randomisation by using a randomisation software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>23/08/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Pernambuco</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hebron Farmaceutica</primarysponsorname>
    <primarysponsoraddress>Av Lins Petit 320/11 Edf. Boa Vista 
CEP: 50070-230
Recife - PE</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Hebron Farmaceutica</fundingname>
      <fundingaddress>Av Lins Petit 320/11 Edf. Boa Vista 
CEP: 50070-230
Recife - PE</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Instituto de Medicina Integral Prof Fernando Figueira (IMIP)</sponsorname>
      <sponsoraddress>Rua dos Coelhos, 300
Boa Vista
CEP: 50070-550
Recife - PE</sponsoraddress>
      <sponsorcountry>Brazil</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Randomized clinical trial to determine the efficacy of Peppermint in infantile colic. It will be a crossover study with one week of intervention of each treatment (Peppermint vs dimethicone). It will be studies 30 healthy infants.</summary>
    <trialwebsite>www.imip.org.br</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Instituto de Medicina Integral Prof Fernando Figueira (IMIP)</ethicname>
      <ethicaddress>Rua dos Coelhos, 300 - Boa Vista
CEP: 50070-550
Recife - PE</ethicaddress>
      <ethicapprovaldate>8/07/2009</ethicapprovaldate>
      <hrec>1/09/1451</hrec>
      <ethicsubmitdate>10/11/2008</ethicsubmitdate>
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Joao Guilherme Bezerra Alves</name>
      <address>Rua dos Coelhos, 300 - Boa Vista
CEP: 50070-550
Recife - PE</address>
      <phone>+558199746351</phone>
      <fax />
      <email>joaoguilher@imip.org.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Marcio Gueiros</name>
      <address>Av Lins Petit 320/11 - Boa Vista
CEP: 50070-230
Recife - PE</address>
      <phone>+558133669294</phone>
      <fax />
      <email>marcio@hebron.com.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>